142 related articles for article (PubMed ID: 38297524)
21. Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial.
Bertrand D; Stouten V; De Cock D; Pazmino S; Doumen M; de Wergifosse I; Joly J; Badot V; Corluy L; Hoffman I; Taelman V; De Knop K; Geens E; Langenaken C; Lenaerts JL; Lenaerts J; Walschot M; Mannaerts J; Westhovens R; Verschueren P
Scand J Rheumatol; 2022 Nov; 51(6):470-480. PubMed ID: 34514929
[TBL] [Abstract][Full Text] [Related]
22. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
23. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
[TBL] [Abstract][Full Text] [Related]
24. High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.
Li R; Zhao JX; Su Y; He J; Chen LN; Gu F; Zhao C; Deng XR; Zhou W; Hao YJ; Xue Y; Liu HX; Zhao Y; Zou QH; Liu XY; Zhu P; Sun LY; Zhang ZL; Zou HJ; Li XF; Liu Y; Fang YF; Keystone E; McInnes IB; Li ZG
Medicine (Baltimore); 2016 Jul; 95(28):e3968. PubMed ID: 27428186
[TBL] [Abstract][Full Text] [Related]
25. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP; Jasenecova M; Vasconcelos JC; Filer A; Raza K; Qureshi S; D'Agostino MA; McInnes IB; Isaacs JD; Pratt AG; Fisher BA; Buckley CD; Emery P; Ho P; Buch MH; Ciurtin C; van Schaardenburg D; Huizinga T; Toes R; Georgiou E; Kelly J; Murphy C; Prevost AT;
Lancet; 2024 Mar; 403(10429):838-849. PubMed ID: 38364839
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
27. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
28. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
Huizinga TW; Conaghan PG; Martin-Mola E; Schett G; Amital H; Xavier RM; Troum O; Aassi M; Bernasconi C; Dougados M
Ann Rheum Dis; 2015 Jan; 74(1):35-43. PubMed ID: 25169728
[TBL] [Abstract][Full Text] [Related]
29. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
31. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
Coates LC; Moverley AR; McParland L; Brown S; Navarro-Coy N; O'Dwyer JL; Meads DM; Emery P; Conaghan PG; Helliwell PS
Lancet; 2015 Dec; 386(10012):2489-98. PubMed ID: 26433318
[TBL] [Abstract][Full Text] [Related]
32. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
[TBL] [Abstract][Full Text] [Related]
33. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Rech J; Hueber AJ; Finzel S; Englbrecht M; Haschka J; Manger B; Kleyer A; Reiser M; Cobra JF; Figueiredo C; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Schett G
Ann Rheum Dis; 2016 Sep; 75(9):1637-44. PubMed ID: 26483255
[TBL] [Abstract][Full Text] [Related]
34. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
35. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
36. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA).
Jung SM; Pyo JY; Lee SW; Song JJ; Lee SK; Park YB
Semin Arthritis Rheum; 2020 Dec; 50(6):1414-1420. PubMed ID: 32241617
[TBL] [Abstract][Full Text] [Related]
38. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
39. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study.
Marsal S; Corominas H; de Agustín JJ; Pérez-García C; López-Lasanta M; Borrell H; Reina D; Sanmartí R; Narváez J; Franco-Jarava C; Peterfy C; Narváez JA; Sharma V; Alataris K; Genovese MC; Baker MC
Lancet Rheumatol; 2021 Apr; 3(4):e262-e269. PubMed ID: 38279410
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
